also reports that the NLRP3 inflammasome blocking attenuates COVID‐19‐related proinflammatory cytokines release in cells and mice, indicating that targeting the NLRP3 inflammasome would be a potential target for severe COVID‐19 therapy. This evidence concerns the gene NLRP3 and COVID-19.